DR. HEMA SALVADY

PRESENT POSITION & ADDRESS >

Clear Lake Rheumatology
2006 to Present
2060 Space Park Dr.
Suite 208
Nassau Bay, Texas 77058
Ph: (281) 957-9127
Fax: (281) 957-9157
Website: www.clearlakerheumatology.com
Email: drsalvady@clearlakerheumatology.com

Accurate Clinical Research, Inc.
Sub-Investigator
Jul 2010 to Present
2060 Space Park Drive, Suite 208
Nassau Bay, TX 77058
Email:hsalvady@accurateclinicalresearch.com


BIOGRAPHICAL INFORMATION >

Citizenship: U.S.A

CERTIFICATION >

ECFMG Certification

BOARD CERTIFICATION >

Board Certified in Rheumatology
M.B.B.S (Licensed to practice in India)


EDUCATION >

Fellowship > Rheumatology

Wayne State University
Detroit Medical Center, Detroit MI
Sep 2001 to Aug 2003

Internship & Residency

Internal Medicine
Conemaugh Memorial Medical Center

Johnstown, PA

July 1998 to June 2001

Medical Experience & Training

Transitional Year Residency in Medicine Conemaugh Memorial Medical Center, Johnstown, PA February 1997 to July 1998

Externship in Family Practice Sinai Hospital, Detroit, MI June 1996 to July 1996

Diploma in Clinical Pathology Gandhi Medical College, Bhopal, India September 1991 to August 1992

Resident House Officer Dept. of Medicine, Kasturba Hospital, Affiliated to Gandhi Medical College, Bhopal, India September 1990 to August 1991

Degree & Undergraduate Study

M.B.B.S
Gandhi Medical College, Bhopal – India
Sep 1984 to Aug 1989

Bachelor of Science
MLB Girls College,Bhopal – India
Jun 1983 to Jun 1984


PROFESSIONAL MEMBERSHIPS >

Member- American College of Rheumatology
Member-American College of Physicians
Member-American Medical Association
Member-Texas Medical Association
Member-Galveston County Medical Society

HOSPITAL PRIVILEGES >

Courtesy Privileges, Houston Methodist St. John Hospital, Nassau Bay, Texas

LICENSURE >

State of Texas- M1374


PROFESSIONAL EXPERIENCE >

Jul 10 – Current

Private practice as a Rheumatologist, Clearlake Rheumatology – 2060 Space Park Dr, Nassau Bay, TX

Feb 08 – June 10

Working as a Rheumatologist with Texas Gulf Coast Medical Group, Webster, TX

Nov 03 – Dec 07

Worked as a Rheumatologist with Kelsey-Seybold Clinic, Houston, TX

Sept 01 – Aug 03

Fellowship in Rheumatology at Wayne State University/ Detroit Medical Center, Detroit, MI

July 98 – June 01

Internal Medicine Residency at Conemaugh Memorial Medical Center, Johnstown, PA

Feb 97 – July 98

Transitional Year Residency in Medicine at Conemaugh Memorial Medical Center, Johnstown, PA

Jun 96 – July 96

Externship in Family Practice, Sinai Hospital, Detroit, MI

Jan 93 – Dec 93

Medical Officer, P. Ratnaswamy Hospital, Trivandrum, India

Sept 92 – Dec 92

Junior Medical Officer , Kasturba Hospital, B.H.E.L., Bhopal, India

Sept 91 – Aug 92

Diploma in Clinical Pathology, Gandhi Medical College, Bhopal, India

Sept 90 – Aug 91

Resident House Officer, Dept. of Medicine, Kasturba Hospital, Affiliated to Gandhi Medical College, Bhopal, India

Sept 89 – Aug 90

Compulsory Rotatory Residential Internship in Hospitals affiliated to Gandhi Medical College, Bhopal, India

Sept 84 – Aug 89

Bachelor of Medicine and Bachelor of Surgery( MBBS), Gandhi Medical College, Bhopal, India


RESEARCH EXPERIENCES >

Aug 95 – Mar 96

Research Assistant, Dept of Immunology, Wayne State University, Detroit, MI


CLINICAL TRIALS >

Sub-Investigator, 2015 Lilly, Phase III I1F-MC-RHBE: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients with Active Psoriatic Arthritis

Sub-Investigator, 2014 Pfizer, Phase III, B5371002: A Phase 3 Randomized, Double-Blind Study Assessing the Efficacy and Safety Of Pf-06438179 and Infliximab in Combination with Methotrexate in Subjects with Moderately to Severely Active Rheumatoid Arthritis who have had an Inadequate Response to Methotrexate

Sub-Investigator, 2014 Lilly, Phase II, I5Q-MC-CGAF: A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 In Patients with Mild to Moderate Osteoarthritis Pain of the Knee

Sub-Investigator, 2014 AbbVie, Phase II, M13-538: Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with ABT-494

Sub-Investigator, 2014 Takeda, Phase II, FEB-XR_201: A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment

Sub-Investigator, 2014 Pfizer, Phase IIIb/IV, A3921133: Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis

Sub-Investigator, 2014 HGS, Observational, HGS1006-C1124: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab)

Sub-Investigator, 2014 Sanofi, Phase III, MSC12665 (SARIL-RA-EASY): A multicenter, randomized, open-label, parallel-group usability study of the sarilumab auto-injector device and a prefilled syringe in patients with moderate to severe active rheumatoid arthritis who are candidates for anti-IL6R therapy

Sub-Investigator, 2014 AbbVie, Phase II, M13-550: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy

Sub-Investigator, 2013 Roche, Phase III, ML28338: A Multicenter, Open Label Long Term Extension Study of WA22762 and NA25220 to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Sub-Investigator, 2013 Novartis, Phase III, CAIN457F2306E1: A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis

Sub-Investigator 2013, A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs

Sub-Investigator 2013, A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy,

Sub-Investigator 2013, A Phase 3 study that investigates the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study

Sub-Investigator, 2012: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination with Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults with Early Active Rheumatoid Arthritis

Sub-Investigator, 2012: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol

Sub-Investigator, 2011: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess The Long Term Safety, Tolerability and Efficacy Up To 2 Years in Patients with Active Psoriatic Arthritis

Sub-Investigator, 2011: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to Anti-TNFa Agents

Sub-Investigator, 2011: Epidemiological Study of Fibromyalgia in the United States

Sub-Investigator, 2011: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)

Sub-Investigator, 2011: A Phase 3, 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg S.C. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

Sub-Investigator, 2011: A Phase 3, A Randomized, Double-Blind, Active-Controlled Study of Canakinumab (ACZ885) Pre-Filled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients.

Sub-Investigator, 2011: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)

Sub-Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).

Sub-Investigator, 2011: A Phase 4, Multicenter, Randomized, 52-Week Study to Evaluate the Routine Assessment of Patient Index Data (Rapid3) Compared to the Clinical Disease Activity Index (CDAI) to Prospectively Predict Treatment Success at 52 Weeks Based on a Treatment Decision at Week 12 in Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Certolizumab Pegol (CZP)

Sub-Investigator, 2011: A Phase 3, Randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis

Sub-Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy

Sub-Investigator, 2011: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

Sub-Investigator, 2011: A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis Who Completed Study RA0056

Sub-Investigator, 2010: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF–Blocker Therapy,/p>

Sub-Investigator, 2010: A Phase 2, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy

Sub-Investigator, 2010: A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Participants With Rheumatoid Arthritis